Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis

Summary

This study will evaluate the safety of the administration of a copper chelating agent, tetrathiomolybdate, for patients with idiopathic pulmonary fibrosis that have failed previous treatment. The primary endpoint for this study is safety with secondary endpoints including change in pulmonary function, exercise capacity, and quality of life.

Timeline

Start

2003-03

Primary completion

2006-05

Completion

2006-05

Drugs

Indications